I posted how many employees they had. 6500 employees or so. (They probably have 20 different vp's of this or that branch)
And later that Reny Aniline wasn't on the website either.
All of them are employees whether they are one of the 30 or so people listed under team members on Natera site or not.
https://www.natera.com/company/leadership-team/#pg-menu-tabs
I was more trying to point out it doesn't matter if they are on the website without going deep into something I didn't think was that important
Wonder what ici gets picked in the upcoming soon to be confirmed in Leron pre-ispy mcrc study.
Tecentriq maybe? That's the one I hope
Let's get Roche in on the fun.
"Yes, Tecentriq (atezolizumab) has notable new formulation and approval updates:
• Subcutaneous Formulation (Tecentriq Hybreza): Approved by the FDA as a subcutaneous (under-the-skin) injection combined with hyaluronidase-tqjs. It takes about 7 minutes to administer, compared to the traditional 30-to-60-minute intravenous (IV) infusion, and is cleared for all adult IV indications.
• New Colon Cancer Approval (October 2026): The FDA approved both Tecentriq (IV) and Tecentriq Hybreza (subcutaneous) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients (2 years and older for IV, and 12 years and older weighing ≥40 kg for subcutaneous) with Stage III mismatch repair deficient (dMMR) colon cancer.
• Small Cell Lung Cancer Approval (October 2025): Approved in combination with lurbinectedin as a first-line maintenance therapy for extensive-stage small cell lung cancer (ES-SCLC).
• Bladder Cancer Approval (May 2026): Approved for adjuvant muscle-invasive bladder cancer with ctDNA-guided treatment.